TWI415833B - 脂氧素（ｌｉｐｏｘｉｎ）ａ4類似物之結晶鉀鹽 - Google Patents

脂氧素（ｌｉｐｏｘｉｎ）ａ4類似物之結晶鉀鹽 Download PDF

Info

Publication number
TWI415833B
TWI415833B TW096146154A TW96146154A TWI415833B TW I415833 B TWI415833 B TW I415833B TW 096146154 A TW096146154 A TW 096146154A TW 96146154 A TW96146154 A TW 96146154A TW I415833 B TWI415833 B TW I415833B
Authority
TW
Taiwan
Prior art keywords
potassium salt
ray powder
powder diffraction
diffraction pattern
crystalline potassium
Prior art date
Application number
TW096146154A
Other languages
English (en)
Chinese (zh)
Other versions
TW200838847A (en
Inventor
哈客 堤洛
葛洛司貝區 丹賈
溫特 加布立爾
山得 邁可
貝克曼 沃夫岡
巴特爾 克勞斯
丁特 克力斯坦
Original Assignee
拜耳知識產權公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39076610&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI415833(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 拜耳知識產權公司 filed Critical 拜耳知識產權公司
Publication of TW200838847A publication Critical patent/TW200838847A/zh
Application granted granted Critical
Publication of TWI415833B publication Critical patent/TWI415833B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C07C59/70—Ethers of hydroxy-acetic acid, e.g. substitutes on the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/48—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
TW096146154A 2006-12-04 2007-12-04 脂氧素（ｌｉｐｏｘｉｎ）ａ4類似物之結晶鉀鹽 TWI415833B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87283006P 2006-12-04 2006-12-04

Publications (2)

Publication Number Publication Date
TW200838847A TW200838847A (en) 2008-10-01
TWI415833B true TWI415833B (zh) 2013-11-21

Family

ID=39076610

Family Applications (1)

Application Number Title Priority Date Filing Date
TW096146154A TWI415833B (zh) 2006-12-04 2007-12-04 脂氧素（ｌｉｐｏｘｉｎ）ａ4類似物之結晶鉀鹽

Country Status (28)

Country Link
US (2) US7906678B2 (https=)
EP (2) EP3489214A1 (https=)
JP (1) JP5410984B2 (https=)
KR (3) KR20090101169A (https=)
CN (1) CN101553456B (https=)
AR (1) AR064116A1 (https=)
AU (1) AU2007327765B2 (https=)
BR (1) BRPI0719679A2 (https=)
CA (1) CA2670791C (https=)
CL (1) CL2007003468A1 (https=)
CO (1) CO6190608A2 (https=)
CR (1) CR10837A (https=)
DO (1) DOP2009000130A (https=)
EA (1) EA018615B1 (https=)
EC (1) ECSP099380A (https=)
IL (1) IL198434A (https=)
MA (1) MA31079B1 (https=)
MX (1) MX2009005911A (https=)
MY (1) MY147951A (https=)
NO (1) NO20092528L (https=)
NZ (1) NZ577338A (https=)
PE (2) PE20120395A1 (https=)
SV (1) SV2009003286A (https=)
TN (1) TN2009000167A1 (https=)
TW (1) TWI415833B (https=)
UY (1) UY30755A1 (https=)
WO (1) WO2008068041A1 (https=)
ZA (1) ZA200904689B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120395A1 (es) * 2006-12-04 2012-05-23 Bayer Ip Gmbh Sal de potasio cristalina de analogos de lipoxina a4
US20090036530A1 (en) * 2006-12-04 2009-02-05 Bayer Schering Pharma Aktiengesellschaft Crystalline acid of lipoxin A4 analogs and method of making
EP2135610A1 (en) 2008-06-20 2009-12-23 Laboratorios Almirall, S.A. Combination comprising DHODH inhibitors and methotrexate
EP2470189A4 (en) * 2009-08-27 2013-01-23 Merck Sharp & Dohme METHOD FOR PRODUCING PROTEASE INHIBITORS OF HEPATITIS C VIRUS
EP2958560B1 (en) * 2013-02-21 2019-05-08 Forsyth Dental Infirmary for Children Methods for increasing oral ostenogenesis using lipoxin a4 (lxa4) and its analogs
EP3270693B1 (en) * 2015-03-18 2021-06-30 Forsyth Dental Infirmary for Children Methods for stabilizing atherosclerotic plaques using lipoxins, resolvins, and analogs thereof
ES2827796T3 (es) * 2016-06-03 2021-05-24 Thetis Pharmaceuticals Llc Composiciones y procedimientos relativos a sales de mediadores pro-resolutivos especializados de inflamación
WO2018144316A1 (en) 2017-01-31 2018-08-09 The Brigham And Women's Hospital, Inc. Alx receptor ligands define a biochemical endotype for inflammation-based diseases
CN111875530A (zh) * 2020-08-17 2020-11-03 浙江朗华制药有限公司 一种普拉西坦水合物晶体及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003040080A2 (en) * 2001-11-06 2003-05-15 Schering Aktiengesellschaft Lipoxin a4 analogs

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650435A (en) * 1991-04-01 1997-07-22 Madara; James L. Modulation of inflammation related to columnar epithelia
JPH08512023A (ja) 1993-06-15 1996-12-17 ブリガム・アンド・ウイメンズ・ホスピタル リポキシン化合物
US5441951A (en) * 1994-06-15 1995-08-15 Brigham & Women's Hospital Lipoxin compounds
US6048897A (en) 1993-06-15 2000-04-11 Brigham And Women's Hospital Lipoxin compounds and their use in treating cell proliferative disorders
WO1995001179A1 (en) 1993-06-29 1995-01-12 Brigham & Women's Hospital Modulation of inflammation related to columnar epithelia
US6008205A (en) 1997-04-04 1999-12-28 The Brigham & Women's Hospital, Inc. Polyisoprenyl phosphate stable analogs for regulation of neutrophil responses
US6236978B1 (en) * 1997-11-14 2001-05-22 New York University System and method for dynamic profiling of users in one-to-one applications
US6006466A (en) * 1998-08-20 1999-12-28 Washecka; John Concealed linear payout holder for fishing leader
SE9900274D0 (sv) 1999-01-28 1999-01-28 Astra Ab New compound
AU780114B2 (en) 1999-03-18 2005-03-03 Brigham And Women's Hospital Regulation of phospholipase D activity
CA2675416A1 (en) 1999-03-18 2000-09-21 Brigham And Women's Hospital Lipoxin compounds and their use
ES2249257T3 (es) 1999-03-18 2006-04-01 The Brigham And Women's Hospital, Inc. Utilizacion de compuestos de lipoxina para la inhibicion de la respuesta de los neutrofilos inducida por tnf-alfa.
ES2215752T3 (es) 1999-11-09 2004-10-16 Alcon, Inc Lipoxina a4 y analogos para el tratamiento del ojo seco.
AU2001249329A1 (en) 2000-03-20 2001-10-03 Brigham And Women's Hospital Lipoxin analogs and methods for the treatment of periodontal disease
AU2002347539A1 (en) 2001-12-13 2003-06-23 Ranbaxy Laboratories Limited Crystalline cefdinir potassium dihydrate
JP4634716B2 (ja) 2002-03-15 2011-02-16 ドクター・レディーズ・ラボラトリーズ・リミテッド ５−［４−［［３−メチル−４−オキソ−３，４−ジヒドロキナゾリン−２−イル］メトキシ］ベンジル］チアゾリジン−２，４−ジオンカリウム塩の新規な結晶形
SI1589966T1 (sl) 2003-01-30 2011-06-30 Lek Pharmaceuticals D.D. Postopek čiščenja losartana
WO2006035291A1 (en) 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Crystalline forms of cefdinir potassium
US7223718B2 (en) * 2005-03-07 2007-05-29 Falcon Lab Llc Enhanced glyphosate herbicidal concentrates
WO2007053724A2 (en) 2005-10-31 2007-05-10 Teva Pharmaceutical Industries Ltd. Crystalline forms of cefdinir potassium salt
PE20120395A1 (es) * 2006-12-04 2012-05-23 Bayer Ip Gmbh Sal de potasio cristalina de analogos de lipoxina a4

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003040080A2 (en) * 2001-11-06 2003-05-15 Schering Aktiengesellschaft Lipoxin a4 analogs

Also Published As

Publication number Publication date
WO2008068041A1 (en) 2008-06-12
NZ577338A (en) 2011-02-25
UY30755A1 (es) 2008-07-31
EA018615B1 (ru) 2013-09-30
DOP2009000130A (es) 2009-08-15
CN101553456A (zh) 2009-10-07
CA2670791C (en) 2017-01-03
IL198434A (en) 2012-09-24
MA31079B1 (fr) 2010-01-04
EP2089350B1 (en) 2018-08-22
MY147951A (en) 2013-02-15
PE20120395A1 (es) 2012-05-23
IL198434A0 (en) 2010-02-17
EP3489214A1 (en) 2019-05-29
AU2007327765B2 (en) 2012-04-12
US7906678B2 (en) 2011-03-15
CA2670791A1 (en) 2008-06-12
CN101553456B (zh) 2013-08-28
KR20090101169A (ko) 2009-09-24
KR20140135847A (ko) 2014-11-26
CO6190608A2 (es) 2010-08-19
MX2009005911A (es) 2009-09-07
ZA200904689B (en) 2011-10-26
TN2009000167A1 (en) 2010-10-18
NO20092528L (no) 2009-08-26
JP5410984B2 (ja) 2014-02-05
JP2010511649A (ja) 2010-04-15
BRPI0719679A2 (pt) 2014-01-14
EA200900732A1 (ru) 2009-12-30
HK1135961A1 (en) 2010-06-18
US20080182897A1 (en) 2008-07-31
CR10837A (es) 2009-07-23
SV2009003286A (es) 2009-10-02
US8049035B2 (en) 2011-11-01
PE20081200A1 (es) 2008-11-06
US20110124910A1 (en) 2011-05-26
AR064116A1 (es) 2009-03-11
EP2089350A1 (en) 2009-08-19
CL2007003468A1 (es) 2008-07-04
AU2007327765A1 (en) 2008-06-12
TW200838847A (en) 2008-10-01
ECSP099380A (es) 2009-11-30
KR20160054030A (ko) 2016-05-13

Similar Documents

Publication Publication Date Title
TWI415833B (zh) 脂氧素（ｌｉｐｏｘｉｎ）ａ4類似物之結晶鉀鹽
KR100704142B1 (ko) 사람 퍼옥시좀 증식 활성화 수용체(ＰＰＡＲ)α의 효능제로서의 치환된 페닐프로피온산 유도체
JP2008540393A (ja) 新規化合物
JP2009167216A (ja) 置換フェニルアルカン酸誘導体及びその用途
JP2007508382A (ja) Ｐｐａｒモジュレータとしてのフェノキシエーテル誘導体
WO2005018628A1 (en) Compounds for the treatment of metabolic disorders
RU2096405C1 (ru) Производные арилсульфонамида, их смеси изомеров или индивидуальные изомеры и их физиологически переносимые аддитивные соли с основаниями и фармацевтическая композиция, обладающая антитромбической активностью
HK1135961B (en) Crystalline potassium salt of lipoxin a4 analogs
US20090036530A1 (en) Crystalline acid of lipoxin A4 analogs and method of making
US20080182901A1 (en) Crystalline acid of lipoxin A4 analogs and method of making
HK1154819A (en) Anhydrous and hydrate forms of crystalline 2- ( (2s, 3r, 4e, 6e, 1oe, 12s) -13- (4-fluorophenoxy) -2,3, 12- (trihydroxytrideca-4, 6, 10-trien-8-ynyl) oxy) acetic acid
CN102036714A (zh) 晶体2-((2s，3r，4e，6e，10e，12s)-13-(4-氟苯氧基)-2，3，12-三羟基十三碳-4，6，10-三烯-8-炔)氧基)乙酸的无水形式和水合物形式
JP2006528200A (ja) Ｌｘｒアゴニストを用いる治療方法
US4529737A (en) Analgesic and anti-inflammatory arylalkanoic acid phthalidyl esters and pharmaceutical compositions thereof
JP2002371033A (ja) ω−アリール−α−置換脂肪酸誘導体
JP2004123643A (ja) ω−アリール−α−置換脂肪酸誘導体を含有する糖尿病予防剤、治療剤
JP2520416B2 (ja) ω−〔〔〔５−（置換ベンジルチオ）チアジアゾ−ル−２−イル〕チオメチル〕フエノキシ〕アルキルカルボン酸
EP0120270A2 (en) Furyloxazolylacetic acid derivative, processes for preparing same and pharmaceutical composition
WO1981001553A1 (fr) Derives de l'acide oxalylacetique
ZA200600713B (en) Device for fixing a longitudinal carrier to a bone fixing element

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees